- Research
- Open Access
Prevalence of resistant hypertension and associated factors for blood pressure control status using Korean ambulatory blood pressure monitoring registry data
- Received: 10 November 2015
- Accepted: 21 January 2016
- Published: 27 January 2016
The Erratum to this article has been published in Clinical Hypertension 2016 22:14
Abstract
Background
Resistant hypertension (RH) may be one of the cause of the plateau in improving the control rate in hypertension (HT) management. The misdiagnosis of RH by clinic blood pressure (BP) is important clinical problem. Aim of the study were to investigate the prevalence of RH by ambulatory blood pressure monitoring (ABPM) and the factor associated with control status of ambulatory BPs.
Methods
For 1230 subjects taking one or more antihypertensive medication (AHM) enrolled in the Korean Ambulatory Blood Pressure Monitoring (Kor-ABP) registry, the prevalence of RH was calculated which was defined as uncontrolled BP by three AHM classes including diuretic or BP in need of four or more AHM classes. The prevalence determined by clinic versus ambulatory BP was compared.
Results
The age was 59.3 ± 12.5 years, and 44.3 % were female (n = 1230). Among them 72 subjects were taking three AHM drugs including diuretics and 105 subjects were taking four or more AHM classes. With uncontrolled daytime ambulatory BP in 41 among 72 subjects, prevalence of RH was 11.9 % (146/1230). By using nighttime BP criteria, there was significant difference in the prevalence of RH for clinic versus nighttime BP (146/177 vs. 159/177, p = 0.0124). For control status of daytime BP, masked uncontrolled BP was 16.9 % and controlled BP with white-coat effect was 14.1 %. For nighttime BP control status, odd ratios for smoking (0.624), drinking (1.512), coronary artery disease (0.604), calcium antagonist (1.705), and loop diuretics (0.454) were all significant.
Conclusion
The prevalence of RH was 11.9 % by daytime BP and it was significantly higher when using nighttime BP criteria. Control status of daytime BP was misclassified in 31.0 %. Smoking, drinking, coronary artery disease, calcium antagonist, and loop diuretics were associated with nighttime BP control status.
Keywords
- Hypertension Resistant to Conventional Therapy
- Ambulatory blood pressure monitoring
- Masked hypertension
- White-coat hypertension
- Hypertension
Background
Resistant hypertension (RH) is defined as the hypertension (HT) which cannot be controlled below the target blood pressure even if treated with three or more antihypertensive medications (AHM) classes one of which was diuretics or HT which requires four or more AHM classes regardless whether the blood pressure was controlled or not [1]. In recent years, the trend in the control rate of HT in the treated patient has reach a plateau just below 70 % in Korean population [2]. Because the control of HT is essential component in preventing cardiovascular events, the obstacle against improving the control rate of HT is a very important clinical issue and the epidemiologic study is also very important to provide a basis for setting up management strategy of RH.
As shown in the recent clinical trial, the learning from the misdiagnosis of RH using only clinic BP made out-of-office BP measurement, preferably ABPM, as the essential component of the evaluation before adopting the new therapeutic modality [3]. So far, there are few studies for the prevalence of the RH by using ABPM in Korean situation. And the amount of the diagnostic error in using clinic BP to diagnose RH was either unknown in general. And as long as the accurate diagnosis of RH using ABPM is concerned, there are few reports regarding the demographic or clinical factors related to the RH.
So the aim of the present study is, firstly, to identify the true prevalence of RH by analyzing the multicenter ABPM registry data in Korea (Kor-ABP registry) and to identify the diagnostic errors of clinic BP in the diagnosis of RH. Secondly, it is to identify the demographic and clinical factor related to the treatment resistant condition in the subject treated three or more AHM classes.
Methods
Subjects
Among 3766 subjects who were enrolled for Kor-ABP registry during the period from 1st August, 2009 to the end of 2012, 1242 subjects with relevant clinical information and who were treated with at least one AHM were selected for the study. The subject was registered by 27 referral hospitals as described in the previous study [4]. The exclusion criteria was estimated glomerular filtration rate (eGFR) calculated by CKD-EPI equation [5] less than 30 ml/min/1.73m2 and finally 1230 subjects was analyzed for the study.
Clinical and laboratory variables
Information included from the medical records covered: age, gender, height, weight, abdominal circumference, presence of diabetes mellitus (DM), hyperlipidemia, presence of clinical cardiovascular disease, time of diagnosis, mode of treatment, and prescribed medications.
And the questionnaire for each subjects included: smoking status, alcohol intake, extent of physical exercise, family history of HT and premature cardiovascular death, past medical history; HT, DM, hyperlipidemia, stroke, coronary artery disease (CAD), and heart failure.
The collected information for the AHM was the commercial names of the drugs and dosing at the time of enrollment.
Clinic BP and ABPM data
Clinic BP was measured using an A&D UA-767, which passed European Society of Hypertension protocol and International Protocol [6]. Clinic BP was defined as the average BP of two measurements one minute apart, with 5 min’ rest before the first measurement.
- 1)
pulse rate above 120 beats per minute
- 2)
systolic or diastolic blood pressure more than 25 mmHg above or below the previous and subsequent readings
- 3)
pulse pressure below 15 mmHg [9].
Definition of RH and groups according to the control status of BP
The definition of the resistant hypertension was uncontrolled BP even if using three drug classes one of which included diuretics or the BP status requiring treatment using four or more drugs regardless of the control status [1]. Optimal dosage criterion was counted only when the dosage of the each drug was >50 % of the maximum recommended or approved dose for hypertension [10]. For example, for Angiotensin converting enzyme inhibitor (ACEI), ramipril 5mg or perindopril 4mg were minimal dosage needed for optimal treatment. Similarly, for example, losartan 50 mg, valsartan 80mg, amlodipine 5mg, diltiazem 90 mg, bisoprolol 2.5 mg, carvedilol 12.5 mg, nebivolol 2.5 mg, dihydrochlorthiazide 12.5 mg, furosemide 20mg, torsemide 5mg, indapamide 2.5mg spironolacton 12.5mg were the minimal required dosage.
BP was categorized as controlled and uncontrolled status according to the various criteria. By clinic BP criterion, the BP lowered below 140/90 mmHg was regarded as controlled status. As for daytime, nighttime, and 24 h BPs, the BPs lowered below 135/85 mmHg, 120/70 mmHg, and 130/80 mmHg were regarded as controlled status, respectively [2, 11].
For the subjects taking three or more AHM including diuretics, according to the control status defined by various criteria, the subject with controlled BP status was grouped as responsive group, whereas the subject with uncontrolled BP status was grouped as the resistant group.
Definitions of the clinical conditions
Dyslipidemia was defined as the total cholesterol ≥ 240 mg/dL, triglyceride ≥ 150 mg/dL, HDL < 45/50 mg/dL in male and female, respectively, or the use of statin. The diabetes was defined as fasting blood glucose ≥ 126 mg/dL, hemoglobin A1C > 6.5 %, or the use of antidiabetic medication. The chronic kidney disease (CKD) was defined as eGFR calculated by CKD-EPI equation between 30 and 60 ml/min/1,73m2 [5]. Smoking was defined as current smoker and drinking was defined as current drinking by the questionnaire. Regular physical exercise was defined as the three or more times of structured exercise per week. Metabolic syndrome (Mets) was defined when the subject had three or more components of impaired fasting blood glucose or diabetes mellitus, obesity defined by increased abdominal circumference (≥90 cm in male; ≥ 80 cm in female) or BMI ≥ 25 kg/m2, triglyceride level ≥ 150 mg/dL, low HDL level, and blood pressure ≥ 130/85 mmHg or a history of hypertension [12]. Global cardiovascular risk (GCR) profiles were determined according to the 2013 Korean Society of Hypertension Guideline [2].
The study protocol was approved by the clinical research ethics committees in all hospitals involved in the study.
Statistical analyses
All data were expressed as mean ± standard deviation. The statistical significance of the differences in mean values was evaluated using student t-test or analysis of variance (ANOVA). The chi square test and Fisher’s exact test were used to ascertain the statistical significance of the categorical difference between groups. The differences in diagnostic category between clinic versus ambulatory BPs were evaluated using McNemar’s test. Test for inter-rater reliability using the kappa test statistics with 95 % confidence interval were performed to determine the consistency of the two methods of measuring blood pressure.
Multiple logistic regression analysis was performed to examine the association between resistant group defined by various BP criteria and the clinical factors. The independent variable included age, sex, Mets, family history of HTN, physical activity, drinking and smoking status, DM, CKD, history of stroke, CAD, heart failure, the use of ACEI or angiotensin receptor blocker (ARB) as renin angiotensin system (RAS) blockade, beta blocker (BB), calcium channel blocker (CCB), and loop diuretics, and the use of optimal dosage. Statistical significance was defined by a confidence interval of 95% and p < 0.05. All data processing and analysis were performed using SAS 9.4 (SAS Institute Inc., Cary, NC, USA).
Results
General characteristics of the study subjects
The age was 59.3 ± 12.5 years, and 44.3 % were female (n = 1230). Body mass index was 25.2 ± 3.7 in male and 24.9 ± 3.6 in female (p = 0.0984). Smoking and drinking were more frequent in male than female (11.8 % vs 0.8%, p <0.0001 and 29.5% vs 7.2%, p < 0.0001). Family history of HT was present in 46.0 %. High GCR was 83.3 % and coronary artery disease, stroke and heart failure were 25.7 %, 12.6 %, and 4.8 %, respectively. CKD was observed in 10.6 %.
ARBs prescribed were irbesartan (23.1 %), olmesartan (19.0% ), telmisartan (15.7 %), valsartan (15.7 %), losartan (12.4 %), candesartan (8.3 %), fimasartan (1.7 %), and eprosartan (4.1 %). Fixed drug combination was prescribed in 48.7 % for ARB and diuretics. The majority of ACEI was perindopril (70.5 %). BBs prescribed were bisoprolol (39.3 %), carvediolol(29.9 %), nebivolol(12.0 %), atenolol(12.0 %), and etc(2.5 %). CCBs prescribed were amlodipine (49.1 %), slow release form of nifedipine (15.7 %), diltiazem (8.3%), and etc (26.8 %). Diuretics prescribed were dihydrochlorthiazide (65.9 %), loop diuretics (17.4 %), indapamide (7.5 %), and spironolactone (6.6 %).
The uses of antihypertensive medications in 1230 study subjects according to the optimal disage criteria
Count by any dosage | Count by 50 % or more of recommended dose | p* | |
|---|---|---|---|
Angiotensin receptor blocker | 714 (57.9 %) | 705 (57.2 %) | 0 |
ACE inhibitor | 166 (13.5 %) | 157 (12.7 %) | 0 |
Beta blocker | 530 (43.0 %) | 456 (37.0 %) | < 0.0001 |
Calcium antagonist | 732 (59.4 %) | 727 (59.0 %) | 0.03 |
Dihydrochlorthiazide | 259 (21.0 %) | 235 (19.1 %) | <0.0001 |
Indapamide | 19 (1.5 %) | 19 (1.5 %) | 0 |
Loop diuretics | 49 (4.0 %) | 47 (3.8 %) | 0.16 |
Spironolactone | 20 (1.6 %) | 20 (1.6 %) | 0 |
Categories of antihypertensive drug regimen | |||
3 drugs including diuretics | 72 (5.9 %) | 83 (6.7 %) | <0.0001 |
4 drugs | 105 (8.5%) | 83 (6.7 %) | |
other 1 or more drugs | 1053(85.6 %) | 1064(86.5 %) |
When the dosage of each drug ≥ 50 % of the maximum recommended or approved dose for hypertension was considered effective treatment, 83 subjects took three drugs including diuretics and 83 subjects took four or more drug classes and the categorization was differed (McNemar p < 0.0001). As for clinic BP, BP of 42 among 83 subjects taking three drugs including diuretics were uncontrolled.
Prevalence of RH
Agreement between clinic blood pressure and ambulatory blood pressure to classify resistant hypertension
Clinic BP | p* | Kappa | |||
|---|---|---|---|---|---|
Non-RH | RH | (95% confidence interval) | |||
Daytime BP | Non-RH | 19 (10.7 %) | 12 (6.8 %) | 0.53 | |
RH | 12 (6.8 %) | 134 (75.7 %) | 1 | (0.3658 ~ 0.6956) | |
Nighttime BP | Non-RH | 11 (6.2 %) | 7 (4.0 %) | 0.37 | |
RH | 20 (11.3 %) | 139 (78.5 %) | 0.01 | (0.1813 ~ 0.5539) | |
24 h BP | Non-RH | 17 (9.6 %) | 8 (10.2 %) | 0.53 | |
RH | 14 (7.9%) | 138 (78.0%) | 0.2 | (0.3638 ~ 0.7049) | |
For the subject taking optimal dosage, the prevalence of RH was 10.1 % (125/1230), 10.4 % (129/1230), 11.2 % (139/1230), 10.8 % (134/1230) according to the criteria by clinic, daytime, nighttime, and 24 h BPs, respectively.
Agreement of clinic BP and ambulatory BP for the diagnosis of RH
Agreement between clinic blood pressure and ambulatory blood pressure in the control status in the subject taking three or more drugs
Clinic BP (mmHg) | p* | Kappa | |||
|---|---|---|---|---|---|
<140/90 | > = 140/90 | (95 % confidence interval) | |||
Daytime BP (mmHg) | <135/85 | 30 (16.9 %) | 25 (14.1 %) | 0.29 | |
> = 135/85 | 30 (16.9 %) | 92 (52.1 %) | 0.5 | (0.1443 ~ 0.4402) | |
Nighttime BP (mmHg) | <120/70 | 19 (10.7 %) | 18 (10.2 %) | 0.18 | |
> = 120/70 | 41 (23.2) | 99 (55.9 %) | 0 | (0.0328 ~ 0.3264) | |
24 h BP (mmHg) | <130/80 | 27 (15.3 %) | 18 (10.2 %) | 0.32 | |
> = 130/80 | 33 (18.6 %) | 99 (55.9 %) | 0.04 | (0.1680 ~ 0.4627) | |
Agreement of the control status in the subject taking three or more AHMs
As shown in Table 3, the control status defined by nighttime and 24 h BP criteria were significantly different compared to the status defined by clinic BP criterion. At least more than 50 % of the subject taking three or more AHMs showed consistently uncontrolled BP regardless of the kind of the criteria applied. Among 177 subjects taking three or more drugs, 117(66.1 %), 122(68.9 %), 140(79.1 %), and 132(74.5 %) were uncontrolled by clinic, daytime, nighttime, 24 h BP criteria. The kappa statistics suggested poor agreement showing that 31.0% (n = 55), 33.4 % (n = 59), and 28.8 % (n = 51) were misclassified as uncontrolled BP due to white-coat effect or misclassified as controlled BP due to masking by the clinic BP. For control status of daytime BP, masked uncontrolled BP was 16.9 % and controlled BP with white-coat effect was 14.1 %. Masked uncontrolled HT was more frequently observed when using nighttime BP criterion than daytime BP criterion (16.9 % vs. 23.1 %, p = 0.0343). Because daytime BPs in 31 subjects were controlled as shown in Table 2, among 105 subjects taking four or more drugs, 91 subjects (86.6 %) as shown in Table 3 were uncontrolled in daytime BP.
Characteristics of the controlled versus uncontrolled BP groups
The comparison according to control status by daytime blood pressure of 135/85 mmHg or greater in response to three or more antihypertensive medications including diuretics
Controlled BP group | Uncontrolled BP group | p | |
|---|---|---|---|
(N = 55) | (N = 122) | ||
Age (yr) | 61.6 ± 11.2 | 61.2 ± 10.4 | 0.84 |
Body mass index (Kg/m2) | 25.7 ± 4.1 | 25.6 ± 3.3 | 0.83 |
Abdominal circumference (cm) | 93.8 ± 10.9 | 91.9 ± 9.3 | 0.28 |
Clinic systolic BP (mmHg) | 135.1 ± 18.2 | 153.8 ± 24.1 | <0.0001 |
Clinic diastolic BP (mmHg) | 80.2 ± 12.3 | 91.5 ± 16.1 | <0.0001 |
Heart rate (beats per minute) | 73.7 ± 14.4 | 75.2 ± 14.8 | 0.58 |
Potassium (mEq/L) | 4 ± 0.4 | 4.1 ± 0.5 | 0.37 |
Creatinine (mg/dL) | 1 ± 0.3 | 0.9 ± 0.2 | 0.14 |
Cholesterol (mg/dL) | 171.4 ± 40.7 | 182.9 ± 44.9 | 0.17 |
Fasting blood glucose (mg/dL) | 114.2 ± 34 | 109.6 ± 34.6 | 0.53 |
Hemoglobin A1C (%) | 6.6 ± 1.9 | 6.3 ± 1.1 | 0.37 |
Triglyceride (mg/dL) | 128.3 ± 54.2 | 148.4 ± 81 | 0.19 |
High density lipoprotein (mg/dL) | 46.7 ± 13.1 | 45.8 ± 10 | 0.67 |
Daytime systolic BP (mmHg) | 121.8 ± 7.9 | 149.6 ± 15.2 | <0.0001 |
Daytime diastolic BP (mmHg) | 74.8 ± 5.3 | 90.9 ± 11.7 | <0.0001 |
Daytime heart rate (bpm) | 71.4 ± 9.6 | 73.9 ± 10.2 | 0.14 |
Nighttime systolic BP (mmHg) | 115.5 ± 14 | 138.5 ± 20.5 | <0.0001 |
Nighttime diastolic BP (mmHg) | 71 ± 9.7 | 83.6 ± 15.4 | <0.0001 |
Nighttime heat rate (bpm) | 61.8 ± 10.3 | 64.8 ± 11.3 | 0.11 |
24 h systolic BP (mmHg) | 121 ± 8.9 | 146.9 ± 15.3 | <0.0001 |
24 h diastolic BP (mmHg) | 73.9 ± 5.8 | 89.5 ± 12.7 | <0.0001 |
24 h heart rate (bpm) | 68.6 ± 9.3 | 71.3 ± 10 | 0.11 |
Smoking | 14.6 % | 11.5 % | 0.57 |
Drinking | 29.1 % | 32.8 % | 0.62 |
Regular physical activity | 43.6 % | 36.9 % | 0.39 |
Family history of SCD | 3.6 % | 6.6 % | 0.35 |
Family history of hypertension | 36.4 % | 46.7 % | 0.2 |
Metabolic syndrome | 47.3 % | 44.3 % | 0.71 |
High global CV risk | 89.1 % | 84.3 % | 0.4 |
Cardiovascular disease history | 60.0 % | 45.1 % | 0.07 |
Coronary artery disease | 36.4 % | 26.5 % | 0.18 |
Stroke | 14.8 % | 9.0 % | 0.25 |
Heart failure | 18.5 % | 5.8 % | 0.01 |
Antihypertensive medication | |||
ACE inhibitor | 14.5 % | 22.1 % | 0.24 |
Angiotensin receptor blocker | 69.1 % | 78.7 % | 0.17 |
Beta blocker | 56.4 % | 74.6 % | 0.02 |
Calcium antagonist | 50.9 % | 69.7 % | 0.02 |
Diuretics | 100.0 % | 99.2 % | 0.5 |
Thiazide | 70.9 % | 78.5 % | 0.27 |
Indapamide | 7.3 % | 5.8 % | 0.71 |
Spironolactone | 5.5 % | 6.6 % | 0.77 |
Loop diuretics | 21.8 % | 10.7 % | 0.05 |
Alpha blocker | 1.8 % | 2.5 % | 0.41 |
Vasodilator | 0.0 % | 2.5 % | 0.55 |
Aspirin | 50.1 % | 54.1 % | 0.76 |
Statin | 40.0 % | 40.9 % | 0.9 |
The factors related to control status
Multiple logistic regression analysis and odds ratios for the factors associated with the resistant group to antihypertensive theraphy using 3 or more antihypertensive medications including diuretics
Clinic BP | Daytime BP | Nighttime BP | 24 h BP | |
|---|---|---|---|---|
3 140/90 mmHg | 3 135/85 mmHg | 3 120/70 mmHg | 3 130/80 mmHg | |
Age | 0.989[0.978 ~ 1.001] | 0.992[0.98 ~ 1.004] | 0.996[0.983 ~ 1.009] | 0.992[0.98 ~ 1.005] |
Male sex | 0.956[0.71 ~ 1.288] | 1.221[0.901 ~ 1.655] | 1.171[0.836 ~ 1.639] | 1.157[0.84 ~ 1.594] |
Metabolic syndrome | 0.965[0.743 ~ 1.253] | 1.037[0.793 ~ 1.357] | 0.963[0.717 ~ 1.294] | 1.043[0.786 ~ 1.385] |
Smoking | 1.202[0.791 ~ 1.827] | 1.161[0.75 ~ 1.797] | 0.624[0.399 ~ 0.976] | 1.008[0.639 ~ 1.59] |
Drinking | 1.135[0.843 ~ 1.528] | 1.242[0.913 ~ 1.688] | 1.512[1.072 ~ 2.133] | 1.4[1.01 ~ 1.942] |
Regular physical exercise | 0.826[0.636 ~ 1.073] | 0.855[0.654 ~ 1.119] | 0.99[0.735 ~ 1.335] | 0.869[0.654 ~ 1.153] |
Family history of hypertension | 1.231[0.947 ~ 1.6] | 1.131[0.865 ~ 1.48] | 1.121[0.834 ~ 1.507] | 1.169[0.88 ~ 1.552] |
Diabetes mellitus | 0.917[0.685 ~ 1.226] | 0.791[0.589 ~ 1.062] | 1.172[0.837 ~ 1.64] | 0.919[0.673 ~ 1.256] |
History of stroke | 1.166[0.786 ~ 1.73] | 1.042[0.701 ~ 1.549] | 1.391[0.874 ~ 2.214] | 1.063[0.699 ~ 1.617] |
History of coronary artery disease | 0.619[0.458 ~ 0.835] | 0.632[0.465 ~ 0.859] | 0.604[0.431 ~ 0.846] | 0.605[0.44 ~ 0.832] |
History of heart failure | 0.896[0.495 ~ 1.623] | 0.559[0.309 ~ 1.009] | 0.638[0.345 ~ 1.179] | 0.646[0.354 ~ 1.178] |
CKD | 1.08[0.709 ~ 1.646] | 1.025[0.67 ~ 1.569] | 1.298[0.79 ~ 2.133] | 1.293[0.815 ~ 2.051] |
Beta blocker | 0.962[0.731 ~ 1.265] | 0.838[0.634 ~ 1.107] | 1.017[0.746 ~ 1.385] | 0.742[0.554 ~ 0.994] |
Calcium antagonist | 1.527[1.176 ~ 1.982] | 1.589[1.218 ~ 2.074] | 1.705[1.271 ~ 2.288] | 1.411[1.066 ~ 1.868] |
ACE inhibitor or ARB | 1.42[1.083 ~ 1.863] | 1.479[1.122 ~ 1.95] | 1.273[0.938 ~ 1.728] | 1.376[1.03 ~ 1.837] |
Loop diuretics | 0.755[0.405 ~ 1.408] | 0.54[0.289 ~ 1.011] | 0.454[0.24 ~ 0.861] | 0.541[0.288 ~ 1.014] |
Optimal dosage use | 1.283[0.838 ~ 1.965] | 1.285[0.836 ~ 1.976] | 1.15[0.72 ~ 1.838] | 1.086[0.696 ~ 1.696] |
Demographic and clinical factors related to uncontrolled BP group when treated with three or more antihypertensive medications including diuretics. In the upper panel, CAD history, the use of calcium channel blocker or the use of ACEI/ARB were significant factor for uncontrolled BP group. In the lower left panel, additionally smoking, drinking, and loop diuretics were significantly related factor for uncontrolled BP group defined by nighttime BP ≥ 120/70 mmHg. In the lower right panel, CAD history, the use of calcium channel blocker or the use of ACEI/ARB were associated with uncontrolled BP group defined by 24 h BP ≥ 130/80 mmHg. ACEI, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker; BP, blood pressure ; CAD, coronary artery disease; CKD, chronic kidney disease; DM, diabetes mellitus; HT, hypertension
Discussion
The most important finding of the present study is that the prevalence of RH is 11.9 %, which was within the 95 % confidence interval of the prevalence of the previous reports [13]. As noted in that meta-analysis, as a cause of the pseudo-RH, the role of ABPM to avoid misdiagnosis was clearly demonstrated in our study [13]. As shown in our study (Table 3), the misclassification for the control status is expected in about 30 % by the presence of white-coat effect or masked uncontrolled hypertensions without using ABPM or other out-of-office BP measurement, possibly, home BP monitoring. As for the role of ABPM in RH, the misdiagnosis of RH was relatively small (6.8 %) each for white-coat effect and masked uncontrolled BP because all of the subject taking four or more drugs were classified as RH regardless of the control status. So the role of ABPM is more important when evaluating the control status which is closely related to the choice of the further therapy. Moreover once the BP was not controlled by one or two AHMs, our study showed that the response to the treatment by using three or more AHMs even including diuretics in almost all subjects was quite poor (control rate less than 31 %). Much more effective treatment modality, such as more active use of aldosterone antagonist and/or renal denervation for selected patients should be prescribed accurately for the right patient using ABPM [14, 15].
And without considering the optimal dosage criteria, the prevalence was overestimated by 1 ~ 2 % in our study which was partially consistent but the difference was not as striking as reported in the previous study [10].
In addition, our study identified the related clinical factor for the uncontrolled BP group in spite of medical therapy using 3 or more AHMs including diuretics in a multivariate model including optimal dosage criterion. There was no relation suggested by Mets to uncontrolled BP group. It can be explained by the risk profile of subjects requiring three or more drugs and coronary artery disease patients too different to be compared with the most populations where Mets implied cardiovascular risk [16]. Smoking was usually known to be associated with elevation of daytime BP or masked HT. So smoking could induce overestimation of the daytime BP so that the nighttime BP should be lower than nonsmoker [17]. The relation of smoking to RH by clinic BP as shown in a previous study was not reproduced in this study probably due to small sample size [18]. The adverse effect of drinking was significant for uncontrolled BP group for nighttime and 24 h BPs. Because heavy drinking itself can be associated with RH and because nighttime BP is of prognostic importance [19], further study is needed regarding the amount of alcohol intake and the influence on the nighttime BP in RH [20]. The definition of uncontrolled BP group separately from RH seems to be better to avoid confusion but because only a minor proportion of BP in the subject treated with four or more drugs was controlled, its clinical implication needs further study.
Our study showed that CAD is consistently associated with controlled group. This finding can be potentially explained by routine use of beta blockade or RAS blockade when BP level is tolerable. Another interesting finding of our study is that heart failure is associated with daytime controlled BP group. This finding also can be explained by the standard regimen of heart failure which includes RAS blockade, beta blocker, and diuretics which mimics RH situation. Specifically, systolic heart failure patients are so sensitive to the dosage of AHM that they usually have relatively low or well controlled BP. This postulation is partly consistent with the finding that loop diuretics were more frequently prescribed in the controlled BP group. But in RH situation, heart failure itself can be aggravated by high or uncontrolled BP so that multiple drug treatment might not be the result of the standard therapy of heart failure but more likely to be the attempt of controlling BP as the primary reason for heart failure.
In our study, as an independent variable in the multiple logistic regression analysis, “optimal dosage” was included so that the effect of the suboptimal dosage possibly more frequently used in heart failure or CAD could be adjusted. Because the proportion of the heart failure was 4.8% in our study, further study is needed for the relationship between heart failure and the RH.
The relation of AHM class to the uncontrolled BP group is very difficult to explain because our study is a cross-sectional study. The association of ARB is different from the CCB in regard to the nighttime BP. Because CCB is relatively potent drug to reduce BP, the association might demonstrate the perceived role of CCB in RH. But it also could be the result of secondary failure of BP control from sympathetic activation by using CCB. Further prospective study is needed to answer if this finding is due to the pharmacological property of those drugs such as the half-life or specific effect on the nighttime BP. For the loop diuretics, it is very well known that enough diuretic therapy is very important to deal with RH. Our finding is consistent with the role of diuretics in RH. But because its use in heart failure may be a confounding factor, further study is needed.
In terms of ABPM versus home BP monitoring issues, our study showed that the nighttime BP criteria can be characterized by increased prevalence of RH and more clinical factors were related. Even though the diagnostic thresholds by ABPM based on the cardiovascular outcomes have been reported in many studies [21–25], it is reported that the nighttime BP level has the better predictive power for CV events [26]. So the implications of the RH diagnosed by nighttime BP criteria should be studied in future study for the cardiovascular prognosis.
The prevalence of the masked uncontrolled HT and white-coat controlled HT or treated normalized HT in RH was quite similar to the prevalence in general hypertensive subjects [11, 27]. But as shown in our study, because most of the subject had high GCR profile, the clinical implication of masked uncontrolled HTN seems to be much more important to prevent cardiovascular events.
Study limitations
The present study has several limitations. The generalizability can be limited because Kor-ABP registry data was driven by the tertiary referral center. But considering the RH is generally handled by the referral center, our data can be applied for referral center. And for all negative findings in this study such as the relation of MetS, CKD, or the relation of optimal dosage to the control status, it needs careful interpretation because the sample size seemed to be too small to exclude those associations. Secondly, in RH patient, it is crucial to make a differential diagnosis for secondary HT. But in our study, no standardized approach or reliable exclusion for secondary HT was performed. Thirdly, the information about the adherence as the behavioral factor which is important cause of RH was not available in the present study. Finally the relation of the clinical factors to the treatment resistance is not based on the causality because this study is a cross-sectional study.
Conclusions
In conclusion, the prevalence of RH was 11.9 % by daytime BP and it was significantly higher when using nighttime BP criteria. Control status of daytime BP was misclassified in 31 %. Smoking, drinking, coronary artery disease, calcium antagonist, and loop diuretics were associated with nighttime BP control status.
Notes
Declarations
Acknowledgements
This study was supported and organized by the Korean Society of Hypertension and the Working group of blood pressure monitoring in Korean Society of Hypertension.
Principal Investigator
Soon Kil Kim
Investigators
Sang Hong Baek, Seoul St. Mary’s Hospital, The Catholic University of Korea; Sang Hyun Ihm, Y. S. Choi, Byung-Ryul Cho, Kangwon National University Hospital; Woo-Shik Kim, Il Suk Sohn, Kyung Hee University School of Medicine; Jin-Won Jeong, Eun Mi Lee, Wonkwang University College of Medicine; J. H. Cho, Soonchun St. Carollo Hospital; Wan Joo Shim, Korea University Medical College Anam Hospital; Young-Kwon Kim, Dongguk University Ilsan Hospital; J. O. Jeong, Chungnam University College of Medicine; Sung Ha Park, Se-Joong Rim, Yonsei Univeresity College of Medicine; Soon Kil Kim, Jinho Shin, Hanyang University College of Medicine; J. H. Jeong, Chosun University College of Medicine; Myeong-Chan Cho, Chungbuk National Univereisty Hospital; Ju Han Kim, Gye Hoon Kim, Chonnam National University Hospital; Gwang-il I Kim, Seoul National University College of Medicine; Dae-Gyun Park, Kangdong Sacred Hospital, Hallym University; Sahng Lee, Eulji University College of Medicine; Wook Bum Pyun, Ewha Womans University School of Medicine; W. Kim, Gwangjoo Veterans Hospital; S. J. Yoon, NHIC Ilsan Hospital; S. K. Choi, Inje University College of Medicine; W. H. Kim, Chonbuk National University College of Medicine; J. Y. Kim, Wonju College of Medicine, Yonsei University.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Authors’ Affiliations
References
- Calhoun DA, Jones D, Textor S, Goff DC, Murphy TP, Toto RD, et al. Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Circulation. 2008;117:e510–26.View ArticlePubMedGoogle Scholar
- Shin J, Park JB, Kim KI, Kim JH, Yang DH, Pyun WB, et al. 2013 Korean Society of Hypertension guidelines for the management of hypertension: part I–epidemiology and diagnosis of hypertension. Clin Hypertens. 2015;21:11.PubMed CentralView ArticleGoogle Scholar
- Bakris GL, Townsend RR, Liu M, Cohen SA, D’Agostino R, Flack JM, et al. Impact of renal denervation on 24-hour ambulatory blood pressure: results from SYMPLICITY HTN-3. J Am Coll Cardiol. 2014;64:1071–8.View ArticlePubMedGoogle Scholar
- Shin J, Park SH, Kim JH, Ihm SH, Kim KI, Kim WS, et al. Discordance between ambulatory versus clinic blood pressure according to global cardiovascular risk group. Korean J Intern Med. 2015;30:610–9.PubMed CentralView ArticlePubMedGoogle Scholar
- Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro 3rd AF, Feldman HI, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150:604–12.PubMed CentralView ArticlePubMedGoogle Scholar
- Rogoza AN, Pavlova TS, Sergeeva MV. Validation of A&D UA-767 device for the self-measurement of blood pressure. Blood Press Monit. 2000;5:227–31.View ArticlePubMedGoogle Scholar
- Haensel A, Utech K, Langewitz W. Validation of TONOPORT V blood-pressure measuring monitor in adults. J Hum Hypertens. 2005;19:745–9.View ArticlePubMedGoogle Scholar
- Verdecchia P, Schillaci G, Boldrini F, Zampi I, Porcellati C. Variability between current definitions of ‘normal’ ambulatory blood pressure. Implications in the assessment of white coat hypertension. Hypertension. 1992;20:555–62.View ArticlePubMedGoogle Scholar
- Verdecchia P, Angeli F, Cavallini C. Ambulatory blood pressure for cardiovascular risk stratification. Circulation. 2007;115:2091–3.View ArticlePubMedGoogle Scholar
- Egan BM, Zhao Y, Li J, Brzezinski WA, Todoran TM, Brook RD, et al. Prevalence of optimal treatment regimens in patients with apparent treatment-resistant hypertension based on office blood pressure in a community-based practice network. Hypertension. 2013;62:691–7.PubMed CentralView ArticlePubMedGoogle Scholar
- Franklin SS, Thijs L, Hansen TW, Li Y, Boggia J, Kikuya M, et al. Significance of white-coat hypertension in older persons with isolated systolic hypertension: a meta-analysis using the International Database on Ambulatory Blood Pressure Monitoring in Relation to Cardiovascular Outcomes population. Hypertension. 2012;59:564–71.PubMed CentralView ArticlePubMedGoogle Scholar
- Park SH, Yoon JS, Won KC, Lee HW. Usefulness of glycated hemoglobin as diagnostic criteria for metabolic syndrome. J Korean Med Sci. 2012;27:1057–61.PubMed CentralView ArticlePubMedGoogle Scholar
- Achelrod D, Wenzel U, Frey S. Systematic review and meta-analysis of the prevalence of resistant hypertension in treated hypertensive populations. Am J Hypertens. 2015;28:355–61.View ArticlePubMedGoogle Scholar
- Williams B, MacDonald TM, Morant S, Webb DJ, Sever P, McInnes G, et al. Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial. Lancet. 2015;386:2059–68.PubMed CentralView ArticlePubMedGoogle Scholar
- Iliescu R, Lohmeier TE, Tudorancea I, Laffin L, Bakris GL. Renal denervation for the treatment of resistant hypertension: review and clinical perspective. Am J Physiol Renal Physiol. 2015;309:F583–94.View ArticlePubMedGoogle Scholar
- Yoon HJ, Ahn Y, Kim KH, Park JC, Choi DJ, Han S, et al. The prognostic implication of metabolic syndrome in patients with heart failure. Korean Circ J. 2013;43:6.Google Scholar
- Hwang E, Choi K, Kang D, Nam G, Jang J, Jeong Y, et al. Prevalence, predictive factor, and clinical significance of white-coat hypertension and masked hypertension in Korean hypertensive patients. Korean J Intern Med. 2007;22:7.View ArticleGoogle Scholar
- Shimbo D, Levitan EB, Booth 3rd JN, Calhoun DA, Judd SE, Lackland DT, et al. The contributions of unhealthy lifestyle factors to apparent resistant hypertension: findings from the Reasons for Geographic And Racial Differences in Stroke (REGARDS) study. J Hypertens. 2013;31:370–6.View ArticlePubMedGoogle Scholar
- Fan HQ, Li Y, Thijs L, Hansen TW, Boggia J, Kikuya M, et al. Prognostic value of isolated nocturnal hypertension on ambulatory measurement in 8711 individuals from 10 populations. J Hypertens. 2010;28:2036–45.View ArticlePubMedGoogle Scholar
- Sarafidis PA, Bakris GL. Resistant hypertension: an overview of evaluation and treatment. J Am Coll Cardiol. 2008;52:1749–57.View ArticlePubMedGoogle Scholar
- Boggia J, Li Y, Thijs L, Hansen TW, Kikuya M, Bjorklund-Bodegard K, et al. Prognostic accuracy of day versus night ambulatory blood pressure: a cohort study. Lancet. 2007;370:1219–29.View ArticlePubMedGoogle Scholar
- Dawes MG, Coats AJ, Juszczak E. Daytime ambulatory systolic blood pressure is more effective at predicting mortality than clinic blood pressure. Blood Press Monit. 2006;11:111–8.View ArticlePubMedGoogle Scholar
- Mesquita-Bastos J, Bertoquini S, Polonia J. Cardiovascular prognostic value of ambulatory blood pressure monitoring in a Portuguese hypertensive population followed up for 8.2 years. Blood Press Monit. 2010;15:240–6.View ArticlePubMedGoogle Scholar
- Kikuya M, Hansen TW, Thijs L, Bjorklund-Bodegard K, Kuznetsova T, Ohkubo T, et al. Diagnostic thresholds for ambulatory blood pressure monitoring based on 10-year cardiovascular risk. Circulation. 2007;115:2145–52.View ArticlePubMedGoogle Scholar
- Thijs L, Hansen TW, Kikuya M, Bjorklund-Bodegard K, Li Y, Dolan E, et al. The International Database of Ambulatory Blood Pressure in relation to Cardiovascular Outcome (IDACO): protocol and research perspectives. Blood Press Monit. 2007;12:255–62.View ArticlePubMedGoogle Scholar
- Dolan E, Stanton A, Thijs L, Hinedi K, Atkins N, McClory S, et al. Superiority of ambulatory over clinic blood pressure measurement in predicting mortality: the Dublin outcome study. Hypertension. 2005;46:156–61.View ArticlePubMedGoogle Scholar
- Celis H, Fagard RH. White-coat hypertension: a clinical review. Eur J Intern Med. 2004;15:348–57.View ArticlePubMedGoogle Scholar
